Lantheus Holdings Inc (NASDAQ:LNTH) Holdings Lifted by Axa

AXA increased its holdings in Lantheus Holdings Inc (NASDAQ:LNTH) by 254.4% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 141,400 shares of the medical equipment provider’s stock after buying an additional 101,500 shares during the period. AXA owned 0.36% of Lantheus worth $4,002,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Pinebridge Investments L.P. boosted its stake in shares of Lantheus by 243.6% during the 2nd quarter. Pinebridge Investments L.P. now owns 33,876 shares of the medical equipment provider’s stock valued at $959,000 after purchasing an additional 24,016 shares in the last quarter. Parametric Portfolio Associates LLC grew its holdings in Lantheus by 73.4% in the second quarter. Parametric Portfolio Associates LLC now owns 95,908 shares of the medical equipment provider’s stock valued at $2,714,000 after purchasing an additional 40,603 shares during the last quarter. Grantham Mayo Van Otterloo & Co. LLC grew its holdings in Lantheus by 154.8% in the second quarter. Grantham Mayo Van Otterloo & Co. LLC now owns 186,800 shares of the medical equipment provider’s stock valued at $5,286,000 after purchasing an additional 113,500 shares during the last quarter. Glen Harbor Capital Management LLC boosted its stake in shares of Lantheus by 100.0% during the second quarter. Glen Harbor Capital Management LLC now owns 2,336 shares of the medical equipment provider’s stock valued at $66,000 after acquiring an additional 1,168 shares during the last quarter. Finally, Tyers Asset Management LLC boosted its stake in shares of Lantheus by 100.0% during the second quarter. Tyers Asset Management LLC now owns 3,212 shares of the medical equipment provider’s stock valued at $91,000 after acquiring an additional 1,606 shares during the last quarter. Institutional investors own 95.72% of the company’s stock.

In other Lantheus news, CEO Mary Anne Heino sold 15,590 shares of the company’s stock in a transaction that occurred on Friday, September 20th. The stock was sold at an average price of $25.81, for a total value of $402,377.90. Following the completion of the transaction, the chief executive officer now owns 582,294 shares of the company’s stock, valued at approximately $15,029,008.14. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, SVP Michael P. Duffy sold 5,604 shares of the company’s stock in a transaction that occurred on Wednesday, September 4th. The shares were sold at an average price of $20.60, for a total value of $115,442.40. Following the completion of the transaction, the senior vice president now directly owns 138,890 shares of the company’s stock, valued at approximately $2,861,134. The disclosure for this sale can be found here. Insiders sold 74,701 shares of company stock worth $1,747,823 in the last 90 days. Corporate insiders own 2.60% of the company’s stock.

A number of analysts have issued reports on the company. ValuEngine lowered Lantheus from a “sell” rating to a “strong sell” rating in a research note on Thursday, October 3rd. CJS Securities raised Lantheus from a “market perform” rating to an “outperform” rating in a research note on Friday, August 16th. Zacks Investment Research raised Lantheus from a “sell” rating to a “hold” rating in a research note on Wednesday, September 25th. Finally, BidaskClub lowered Lantheus from a “buy” rating to a “hold” rating in a research note on Monday, October 7th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and one has issued a buy rating to the stock. Lantheus presently has a consensus rating of “Hold” and a consensus price target of $29.00.

Shares of LNTH traded up $0.41 during mid-day trading on Friday, hitting $18.99. The stock had a trading volume of 433,822 shares, compared to its average volume of 551,848. The company has a market cap of $717.01 million, a PE ratio of 18.85, a PEG ratio of 1.54 and a beta of 1.51. The company’s fifty day simple moving average is $22.81 and its two-hundred day simple moving average is $24.67. The company has a quick ratio of 2.01, a current ratio of 2.62 and a debt-to-equity ratio of 2.05. Lantheus Holdings Inc has a fifty-two week low of $12.59 and a fifty-two week high of $29.80.

Lantheus (NASDAQ:LNTH) last issued its earnings results on Thursday, July 25th. The medical equipment provider reported $0.27 EPS for the quarter, hitting the consensus estimate of $0.27. Lantheus had a return on equity of 51.08% and a net margin of 11.20%. The company had revenue of $85.70 million during the quarter, compared to analyst estimates of $88.72 million. During the same quarter last year, the firm earned $0.25 EPS. The business’s revenue was up .1% on a year-over-year basis. Equities analysts expect that Lantheus Holdings Inc will post 1 earnings per share for the current year.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases worldwide. Its principal products include DEFINITY, a microbubble contrast agent used in ultrasound exams of the heart; and TechneLite, a technetium generator that provides the nuclear material used in nuclear medicine procedures.

Featured Story: What is a Swap?

Institutional Ownership by Quarter for Lantheus (NASDAQ:LNTH)

Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.